Clinical trials · KRAS G12C
KRAS G12C clinical trials in non-small cell lung cancer
The 50 trials Atlas ranked most relevant to KRAS G12C in lung cancer, from first-in-human studies to 8 phase 3 trials, with the phase, status, sponsor and enrollment of each, as registered on ClinicalTrials.gov.
- most relevant trials on KRAS G12C
- 50
- KRAS G12C inhibitors tested
- 6
- phase 3 trials
- 8
- trials recruiting, about to start or ongoing
- 27
KRAS G12C trials at a glance
- 6 inhibitors are in trials: sotorasib (19 trials), adagrasib (16 trials), divarasib (6 trials), olomorasib (4 trials), glecirasib (4 trials) and fulzerasib (2 trials). One trial allows either of two inhibitors, so it counts for both.
- 8 trials are in phase 3: SUNRAY-01 (olomorasib), CodeBreaK 202 (sotorasib), SUNRAY-02 (olomorasib), KRYSTAL-4 (adagrasib), Krascendo 2 (divarasib), KRYSTAL-12 (adagrasib), Krascendo 3 (divarasib), Krascendo 1 (divarasib). Krascendo 1 is the only trial comparing two KRAS G12C inhibitors: divarasib against sotorasib or adagrasib in previously treated disease. Others are randomized against an active comparator too — docetaxel in KRYSTAL-12, the investigator’s choice in Krascendo 3.
- Pembrolizumab is the drug most often registered alongside a KRAS G12C inhibitor, in 10 trials — as a combination partner in some, as the comparator in others; the registry’s intervention list does not say which arm a drug belongs to. Other combinations pair a KRAS G12C inhibitor with SHP2, SOS1, RAF/MEK or EGFR-targeted drugs, antibody–drug conjugates or radiosurgery.
- Where they stand: 16 recruiting; 3 not yet recruiting; 8 active, not recruiting; 4 completed; 1 suspended; 10 terminated; 4 withdrawn; 3 unknown; 1 expanded access.
Trials by KRAS G12C inhibitor
| Inhibitor | Trials | Phase 3 | Open, starting or ongoing | Most frequent lead sponsor |
|---|---|---|---|---|
| Sotorasib | 19 | 1 | 9 | No single sponsor leads16 lead sponsors in total |
| Adagrasib | 16 | 2 | 8 | Mirati Therapeutics Inc.7 lead sponsors in total |
| Divarasib | 6 | 3 | 5 | Hoffmann-La Roche2 lead sponsors in total |
| Olomorasib | 4 | 2 | 3 | Eli Lilly and Company3 lead sponsors in total |
| Glecirasib | 4 | 0 | 3 | No single sponsor leads4 lead sponsors in total |
| Fulzerasib | 2 | 0 | 0 | Innovent Biologics (Suzhou) Co. Ltd. |
The 50 trials
Sorted by phase, then by enrollment. Interventions and sponsors are shown as registered; the list of other interventions does not say which drug is a comparator. Each NCT number opens the registry record.
| Trial | KRAS G12C inhibitor | Other interventions | Population | Phase | Status | Lead sponsor | Start | Enrollment |
|---|---|---|---|---|---|---|---|---|
| NCT06119581SUNRAY-01 | OlomorasibLY3537982 | Pembrolizumab, cisplatin, carboplatin, pemetrexed, placebo | NSCLC | Phase 3 | Recruiting | Eli Lilly and Company | Dec 2023 | 1,264 |
| NCT05920356CodeBreaK 202 | Sotorasib | Pembrolizumab, platinum doublet | NSCLC | Phase 3 | Recruiting | Amgen | Nov 2023 | 750 |
| NCT06890598SUNRAY-02 | Olomorasib | Pembrolizumab, durvalumab, placebo | NSCLC | Phase 3 | Recruiting | Eli Lilly and Company | Mar 2025 | 700 |
| NCT06875310KRYSTAL-4 | Adagrasib | Pembrolizumab, carboplatin, cisplatin, pemetrexed, placebo | NSCLC | Phase 3 | Recruiting | Mirati Therapeutics Inc. | Apr 2025 | 630 |
| NCT06793215Krascendo 2 | Divarasib | Pembrolizumab, carboplatin, cisplatin, pemetrexed | NSCLC | Phase 3 | Recruiting | Hoffmann-La Roche | Oct 2025 | 600 |
| NCT04685135KRYSTAL-12 | AdagrasibMRTX849 | Docetaxel | NSCLC | Phase 3 | Active, not recruiting | Mirati Therapeutics Inc. | Feb 2021 | 453 |
| NCT07541170Krascendo 3 | Divarasib | Pembrolizumab, nivolumab | NSCLC | Phase 3 | Recruiting | Hoffmann-La Roche | Oct 2026 | 400 |
| NCT06497556Krascendo 1 | Divarasib | Sotorasib, adagrasib | NSCLC | Phase 3 | Active, not recruiting | Hoffmann-La Roche | Sep 2024 | 338 |
| NCT04613596KRYSTAL-7 | Adagrasib | Pembrolizumab | NSCLC | Phase 2/3 | Recruiting | Mirati Therapeutics Inc. | Dec 2020 | 626 |
| NCT05853575KRYSTAL 21 | Adagrasib | Two dosing regimens | NSCLC | Phase 2 | Active, not recruiting | Mirati Therapeutics Inc. | Feb 2024 | 200 |
| NCT04625647Lung-MAP | SotorasibAMG 510 | None (monotherapy) | NSCLC | Phase 2 | Active, not recruiting | SWOG Cancer Research Network | Apr 2021 | 116 |
| NCT05311709SOLUCOM | Sotorasib | None (patients with comorbidities) | NSCLC | Phase 2 | Unknown | Vestre Viken Hospital Trust | May 2022 | 100 |
| NCT05609578 | Adagrasib | Pembrolizumab, pemetrexed, cisplatin or carboplatin | NSCLC | Phase 2 | Active, not recruiting | Mirati Therapeutics Inc. | Nov 2022 | 90 |
| NCT07164170 | Glecirasib | ABSK043 | NSCLC | Phase 2 | Recruiting | Abbisko Therapeutics Co, Ltd | Sep 2025 | 86 |
| NCT07639242 | Olomorasib | Pembrolizumab | NSCLC | Phase 2 | Suspended | UNC Lineberger Comprehensive Cancer Center | Oct 2026 | 60 |
| NCT04933695CodeBreaK 201 | Sotorasib | None (first line, monotherapy) | NSCLC | Phase 2 | Terminated | Amgen | Jan 2022 | 42 |
| NCT06582771 | Sotorasib | None (monotherapy) | NSCLC | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | Aug 2024 | 39 |
| NCT05451056 | Sotorasib | None (with a resistance translational study) | NSCLC | Phase 2 | Unknown | Yonsei University | Aug 2022 | 37 |
| NCT07827261 | Glecirasib | BL-B01D1 | NSCLC | Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | Sep 2026 | 36 |
| NCT06248606 | Adagrasib | Stereotactic radiosurgery (untreated brain metastases) | NSCLC | Phase 2 | Recruiting | Ryan Gentzler, MD | Aug 2024 | 30 |
| NCT07543172 | Adagrasib or Sotorasib | CIMAvax-EGF | NSCLC | Phase 2 | Not yet recruiting | Roswell Park Cancer Institute | Oct 2026 | 29 |
| NCT05118854 | Sotorasib | Cisplatin or carboplatin, pemetrexed (neoadjuvant) | NSCLC | Phase 2 | Active, not recruiting | M.D. Anderson Cancer Center | Mar 2022 | 13 |
| NCT06333678 | Sotorasib | Durvalumab | NSCLC | Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | Mar 2024 | 10 |
| NCT05472623Neo-Kan | Adagrasib | Nivolumab (neoadjuvant) | NSCLC | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2023 | 0 |
| NCT05400577 | Sotorasib | None (neoadjuvant, resectable stage IB–IIIA) | NSCLC | Phase 2 | Withdrawn | Fox Chase Cancer Center | Jul 2022 | 0 |
| NCT05815186 | Sotorasib | Ladarixin | NSCLC | Phase 2 | Withdrawn | NYU Langone Health | Apr 2024 | 0 |
| NCT05005234 | FulzerasibGFH925 | None | Solid tumors | Phase 1/2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | Sep 2021 | 334 |
| NCT05789082Krascendo 170 | Divarasib | Pembrolizumab, carboplatin, cisplatin, pemetrexed | NSCLC | Phase 1/2 | Recruiting | Hoffmann-La Roche | Jun 2023 | 320 |
| NCT05074810RAMP 203 | Sotorasib | Avutometinib, defactinib | NSCLC | Phase 1/2 | Active, not recruiting | Verastem, Inc. | Apr 2022 | 153 |
| NCT07227025KaRAnaSa | Olomorasib | Amivantamab | NSCLC | Phase 1/2 | Recruiting | Janssen Research & Development, LLC | Mar 2026 | 60 |
| NCT07339839 | Glecirasib | Ivonescimab | NSCLC | Phase 1/2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Mar 2026 | 42 |
| NCT07012031 | Sotorasib | Trastuzumab deruxtecan | NSCLC | Phase 1/2 | Recruiting | National Cancer Institute (NCI) | Jun 2026 | 37 |
| NCT05002270 | GlecirasibJAB-21822 | Cetuximab | Solid tumors | Phase 1/2 | Completed | Jacobio Pharmaceuticals Co., Ltd. | Sep 2021 | 29 |
| NCT05375994RAMP 204 | Adagrasib | Avutometinib | NSCLC | Phase 1/2 | Completed | Verastem, Inc. | Aug 2022 | 12 |
| NCT05313009 | Sotorasib | Tarloxotinib | NSCLC | Phase 1/2 | Terminated | Medical University of South Carolina | Mar 2022 | 5 |
| NCT06024174 | Adagrasib | BMS-986466, cetuximab | Solid tumors | Phase 1/2 | Terminated | Bristol-Myers Squibb | Nov 2023 | 5 |
| NCT04449874 | DivarasibGDC-6036 | Atezolizumab, cetuximab, bevacizumab, erlotinib, GDC-1971, inavolisib | Solid tumors | Phase 1 | Active, not recruiting | Genentech, Inc. | Jul 2020 | 498 |
| NCT04330664KRYSTAL 2 | AdagrasibMRTX849 | TNO155 | Solid tumors | Phase 1 | Completed | Mirati Therapeutics Inc. | Apr 2020 | 86 |
| NCT05815173 | Sotorasib | Ladarixin | NSCLC | Phase 1 | Recruiting | NYU Langone Health | Aug 2023 | 40 |
| NCT05480865Argonaut | Sotorasib | BBP-398 | Solid tumors | Phase 1 | Terminated | Navire Pharma Inc., a BridgeBio company | Jul 2022 | 28 |
| NCT07382726IZA-A | Adagrasib | Izalontamab brengitecan | NSCLC | Phase 1 | Recruiting | M.D. Anderson Cancer Center | May 2026 | 18 |
| NCT06249282 | Sotorasib | Carfilzomib | NSCLC | Phase 1 | Recruiting | City of Hope Medical Center | Apr 2024 | 15 |
| NCT05497336 | FulzerasibIBI351 | Cetuximab | Colorectal cancer | Phase 1 | Terminated | Innovent Biologics (Suzhou) Co. Ltd. | Aug 2022 | 8 |
| NCT04975256KRYSTAL 14 | AdagrasibMRTX849 | BI 1701963 | Solid tumors | Phase 1 | Terminated | Mirati Therapeutics Inc. | Jul 2021 | 7 |
| NCT05840510KRYSTAL-19 | Adagrasib | nab-Sirolimus | Solid tumors | Phase 1 | Terminated | Mirati Therapeutics Inc. | Aug 2023 | 6 |
| NCT05374538 | Sotorasib | VIC-1911 | NSCLC | Phase 1 | Terminated | Vitrac Therapeutics, LLC | Nov 2022 | 3 |
| NCT06130254 | Adagrasib | Olaparib | Solid tumors | Phase 1 | Terminated | M.D. Anderson Cancer Center | Jan 2024 | 1 |
| NCT05848843 | Adagrasib | Durvalumab | NSCLC | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | Apr 2023 | 0 |
| NCT05273047LungKG12Ci | Sotorasib | None (real-world, observational) | NSCLC | Not applicable | Unknown | Intergroupe Francophone de Cancerologie Thoracique | Mar 2022 | 458 |
| NCT07783009 | Divarasib | None (expanded access program) | NSCLC | Not applicable | Expanded access | Genentech, Inc. | — | — |
How this list was built
We created one Atlas project with the disease “Non-small cell lung cancer”, the target “KRAS G12C” and the keywords “KRAS G12C inhibitor, sotorasib, adagrasib, divarasib, olomorasib, glecirasib”, with precision mode on. Atlas searched the registry, scored each trial against the project and kept 50 of them in the corpus, built on 10 Oct 2026. We then read each of those records on ClinicalTrials.gov again on 30 Oct 2026; phase, status and enrollment are the registry’s values on that date.
These are the 50 most relevant trials, not every trial. Precision mode keeps at most 50 trials per project, ranked by how closely each one matches the disease, the target and the keywords. ClinicalTrials.gov returns about 130 studies for “KRAS G12C” in non-small cell lung cancer (30 Oct 2026), many of which enroll KRAS G12C patients as one cohort among other mutations or tumor types. A project without that limit, or with a narrower question, retrieves more.
40 of the trials are lung cancer studies. 9 enroll several solid tumors and are listed because they include KRAS G12C lung cancer; 1 is a colorectal cancer study, kept by the project for the inhibitor it tests rather than the disease. The list covers ClinicalTrials.gov only: trials registered solely in other registries do not appear. It describes registry records, not results, and is not medical advice. Patients looking for a trial should start from ClinicalTrials.gov and their care team.
The same project is analyzed on the clinical trial landscape page, with phases, statuses and the stated reasons the stopped trials stopped. The registries and literature sources Atlas reads are listed on data sources.
Get this table for your own target
We set up an Atlas project on your disease and target with you, and you get the trials, the papers and the evidence behind them in one place.
Request a demoSource: ClinicalTrials.gov API v2, records read on 30 Oct 2026 for the 50 trials of the Atlas project “KRAS G12C NSCLC Landscape”. Enrollment is the registered target or actual count. Registry data changes; check the record before relying on a value. This table is published under CC BY 4.0: reuse it freely, crediting Helix Research Intelligence with a link to this page.
